Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer treatments. The company's lead product, Folotyn, is approved for the treatment of non-Hodgkin's lymphoma. Allos is dedicated to improving the lives of cancer patients through targeted therapies and novel approaches to treatment.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

7 Patents

#20 in Westminster, CO

#871 in Colorado

#40,006 in US

Westminster, CO, United States of America

Allos Therapeutics, Inc.

Forward Citations = 45

10 inventors:

Gijsbertus J Pronk (3 out of 3 patents)

Michael J Gerber (2 out of 21 patents)

Donald J Abraham (2 out of 25 patents)

4. Stephen J Hoffman (2 out of 5 patents)

5. Martin K Safo (1 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Allos Therapeutics, Inc.. Retrieved from https://idiyas.com/company/allos-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]